{"success":true,"data":{"pressRelease":{"id":"53826","rtpr_id":"nPn4cCWgYa","ticker":"FULC","exchange":"NASDAQ","all_tickers":["FULC"],"title":"FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations","author":"PR Newswire","published_at":"2026-06-03T13:00:21.578Z","article_body":"FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations\n\nPR Newswire\n\nNEW YORK, June 3, 2026\n\nSEC filings reflected insider equity holdings and awards totaling more than\n264,000 shares\n\nNEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ:\nFULC) lost approximately 50% of its value in a single session after disclosing\non June 1, 2026, that the FDA had raised class-wide safety concerns about\nPRC2-targeting agents, leading the Company to discontinue the program of its\nlead candidate pociredir. Shareholders who lost money on their FULC investment\nare encouraged to submit their information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702449-1&h=3867938270&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Ffulcrum-therapeutics-inc-class-action-lawsuit-fulc%3Fprid%3D187399%26wire%3D4&a=submit+their+information+here)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nIn its 10-K filed February 24, 2026, Fulcrum disclosed insider equity\npositions totaling over 260,000 shares for certain executives. The stock\ntraded above $20 in the months preceding the June 1, 2026 disclosure and\ndeclined to approximately $10 following the announcement.\n\nThe 10-K also disclosed a long-term lease commitment of approximately $25.1\nmillion for office and laboratory space, and referenced a CAMP4 Therapeutics\nagreement valued at up to $70 million in milestones plus royalties, with the\nupfront payment not separately quantified.\n\nIf you purchased Fulcrum Therapeutics, Inc. shares and suffered a loss, click\nhere to discuss your legal rights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702449-1&h=1084780897&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Ffulcrum-therapeutics-inc-class-action-lawsuit-fulc%3Fprid%3D187399%26wire%3D4&a=click+here+to+discuss+your+legal+rights)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nSueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years).\nOver 70 professionals. Hundreds of millions recovered.\n\nFrequently Asked Questions About the FULC Investigation\n\nQ: Who is eligible to participate in the FULC investigation?A: Investors who\npurchased FULC stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: Which statements are being investigated as potentially misleading?A: The\ninvestigation concerns whether Fulcrum Therapeutics made materially false or\nmisleading statements regarding insider trading plan disclosures, financial\ncommitments, and the status of its pociredir program. When the FDA's safety\nconcerns were disclosed, the stock price declined approximately 50%.\n\nQ: How much did FULC stock drop?A: Shares fell approximately 50% in a single\nsession after the company disclosed FDA safety concerns about the PRC2\ninhibitor class and simultaneously discontinued its lead candidate pociredir.\nInvestors who purchased shares at higher prices may be entitled to\ncompensation.\n\nQ: What do FULC investors need to do right now?A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or (888) SueWallSt. No immediate action is\nrequired to remain eligible to participate in the investigation.\n\nQ: What does it cost me to participate?A: Nothing. Securities investigations\nand any resulting actions are handled on a pure contingency basis. No upfront\nfees, no retainer, no out-of-pocket costs.\n\nQ: What if I already sold my FULC shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought FULC and sold at a loss may still participate in\nthe investigation.\n\nQ: Do I need to go to court or give testimony?A: No. Participating in the\ninvestigation does not require court appearances or depositions. If legal\naction is later pursued, the overwhelming majority of affected investors never\nappear in court either.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations-302789610.html\n(https://www.prnewswire.com/news-releases/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations-302789610.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4cCWgYa","title":"FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations","author":"PR Newswire","ticker":"FULC","created":"2026-06-03T13:00:21.578Z","tickers":["FULC"],"exchange":"NASDAQ","article_body":"FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations\n\nPR Newswire\n\nNEW YORK, June 3, 2026\n\nSEC filings reflected insider equity holdings and awards totaling more than\n264,000 shares\n\nNEW YORK, June 3, 2026 /PRNewswire/ -- Fulcrum Therapeutics, Inc. (NASDAQ:\nFULC) lost approximately 50% of its value in a single session after disclosing\non June 1, 2026, that the FDA had raised class-wide safety concerns about\nPRC2-targeting agents, leading the Company to discontinue the program of its\nlead candidate pociredir. Shareholders who lost money on their FULC investment\nare encouraged to submit their information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702449-1&h=3867938270&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Ffulcrum-therapeutics-inc-class-action-lawsuit-fulc%3Fprid%3D187399%26wire%3D4&a=submit+their+information+here)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\n(https://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.html)\n\nIn its 10-K filed February 24, 2026, Fulcrum disclosed insider equity\npositions totaling over 260,000 shares for certain executives. The stock\ntraded above $20 in the months preceding the June 1, 2026 disclosure and\ndeclined to approximately $10 following the announcement.\n\nThe 10-K also disclosed a long-term lease commitment of approximately $25.1\nmillion for office and laboratory space, and referenced a CAMP4 Therapeutics\nagreement valued at up to $70 million in milestones plus royalties, with the\nupfront payment not separately quantified.\n\nIf you purchased Fulcrum Therapeutics, Inc. shares and suffered a loss, click\nhere to discuss your legal rights\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4702449-1&h=1084780897&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Ffulcrum-therapeutics-inc-class-action-lawsuit-fulc%3Fprid%3D187399%26wire%3D4&a=click+here+to+discuss+your+legal+rights)\n. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or by telephone at (888) SueWallSt.\n\nSueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years).\nOver 70 professionals. Hundreds of millions recovered.\n\nFrequently Asked Questions About the FULC Investigation\n\nQ: Who is eligible to participate in the FULC investigation?A: Investors who\npurchased FULC stock or securities and suffered financial losses may be\neligible. Eligibility is based on purchase date and documented losses -- not\non whether you still hold the shares.\n\nQ: Which statements are being investigated as potentially misleading?A: The\ninvestigation concerns whether Fulcrum Therapeutics made materially false or\nmisleading statements regarding insider trading plan disclosures, financial\ncommitments, and the status of its pociredir program. When the FDA's safety\nconcerns were disclosed, the stock price declined approximately 50%.\n\nQ: How much did FULC stock drop?A: Shares fell approximately 50% in a single\nsession after the company disclosed FDA safety concerns about the PRC2\ninhibitor class and simultaneously discontinued its lead candidate pociredir.\nInvestors who purchased shares at higher prices may be entitled to\ncompensation.\n\nQ: What do FULC investors need to do right now?A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact SueWallSt\nfor a free, no-obligation evaluation at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com) or (888) SueWallSt. No immediate action is\nrequired to remain eligible to participate in the investigation.\n\nQ: What does it cost me to participate?A: Nothing. Securities investigations\nand any resulting actions are handled on a pure contingency basis. No upfront\nfees, no retainer, no out-of-pocket costs.\n\nQ: What if I already sold my FULC shares -- can I still recover losses?A: Yes.\nEligibility is based on when you purchased, not whether you still hold the\nshares. Investors who bought FULC and sold at a loss may still participate in\nthe investigation.\n\nQ: Do I need to go to court or give testimony?A: No. Participating in the\ninvestigation does not require court appearances or depositions. If legal\naction is later pursued, the overwhelming majority of affected investors never\nappear in court either.\n\nCONTACT:\nSueWallSt\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\nTel: (888) SueWallSt\nFax: (212) 363-7171\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations-302789610.html\n(https://www.prnewswire.com/news-releases/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations-302789610.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2937620/suewallst_logo_1_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-03T13:00:21.655856705Z","server_sent_at_ms":1780491621655},"received_at":"2026-06-03T13:00:21.731Z","source_url":"https://www.prnewswire.com/news-releases/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations-302789610.html"},"analysis":{"id":"43258","press_release_id":"53826","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt issued a press release soliciting shareholders of Fulcrum Therapeutics (FULC) to contact the firm regarding potential securities law violations.\n\nThe firm cites the ~50% stock drop following FDA safety concerns about PRC2-targeting agents and the discontinuation of lead candidate pociredir as the basis for the investigation.\n\nThe release includes standard boilerplate encouraging investors to submit information for a free, no-obligation evaluation on a contingency basis.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"insider_shares":"264,000","lease_commitment":"$25.1 million","partnership_value":"$70 million"}},"quotedText":"Shareholders who lost money on their FULC investment are encouraged to submit their information here","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at SueWallSt"},{"name":"Ed Korsinsky","role":"Attorney at SueWallSt"}],"products":["pociredir"],"companies":[{"name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","relationship":"target"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"CAMP4 Therapeutics","relationship":"partner"}],"dollarAmounts":[{"amount":"$20","context":"stock price prior to June 1 disclosure"},{"amount":"$10","context":"stock price following June 1 disclosure"},{"amount":"$25.1 million","context":"long-term lease commitment"},{"amount":"$70 million","context":"CAMP4 Therapeutics agreement milestones"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by SueWallSt (Levi & Korsinsky). It contains standard solicitation language ('encouraged to submit', 'no cost or obligation') and no new disclosure from the issuer. Per guardrails, this is low-impact noise."},"tickerRelevance":{"others":[{"ticker":"FULC","relevance":"target of investigation"}],"primary":"FULC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"marketCapAdjustment":"low"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt issued a press release soliciting shareholders of Fulcrum Therapeutics (FULC) to contact the firm regarding potential securities law violations.\n\nThe firm cites the ~50% stock drop following FDA safety concerns about PRC2-targeting agents and the discontinuation of lead candidate pociredir as the basis for the investigation.\n\nThe release includes standard boilerplate encouraging investors to submit information for a free, no-obligation evaluation on a contingency basis.","key_figures":{"customDimensions":{"insider_shares":"264,000","lease_commitment":"$25.1 million","partnership_value":"$70 million"}},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Attorney at SueWallSt"},{"name":"Ed Korsinsky","role":"Attorney at SueWallSt"}],"products":["pociredir"],"companies":[{"name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","relationship":"target"},{"name":"SueWallSt","relationship":"plaintiff law firm"},{"name":"CAMP4 Therapeutics","relationship":"partner"}],"dollarAmounts":[{"amount":"$20","context":"stock price prior to June 1 disclosure"},{"amount":"$10","context":"stock price following June 1 disclosure"},{"amount":"$25.1 million","context":"long-term lease commitment"},{"amount":"$70 million","context":"CAMP4 Therapeutics agreement milestones"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-04T06:30:57.695Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"marketCapAdjustment":"low"}},"durationMs":59068,"modelName":"george-droid-qwen-72b"}}